196 related articles for article (PubMed ID: 11751483)
1. A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer.
Chi KN; Gleave ME; Klasa R; Murray N; Bryce C; Lopes de Menezes DE; D'Aloisio S; Tolcher AW
Clin Cancer Res; 2001 Dec; 7(12):3920-7. PubMed ID: 11751483
[TBL] [Abstract][Full Text] [Related]
2. A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer.
Tolcher AW; Kuhn J; Schwartz G; Patnaik A; Hammond LA; Thompson I; Fingert H; Bushnell D; Malik S; Kreisberg J; Izbicka E; Smetzer L; Rowinsky EK
Clin Cancer Res; 2004 Aug; 10(15):5048-57. PubMed ID: 15297406
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer.
Rago RP; Einstein A; Lush R; Beer TM; Ko YJ; Henner WD; Bubley G; Merica EA; Garg V; Ette E; Harding MW; Dalton WS
Cancer Chemother Pharmacol; 2003 Apr; 51(4):297-305. PubMed ID: 12721757
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer.
Morris MJ; Tong WP; Cordon-Cardo C; Drobnjak M; Kelly WK; Slovin SF; Terry KL; Siedlecki K; Swanson P; Rafi M; DiPaola RS; Rosen N; Scher HI
Clin Cancer Res; 2002 Mar; 8(3):679-83. PubMed ID: 11895895
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer.
Rudin CM; Kozloff M; Hoffman PC; Edelman MJ; Karnauskas R; Tomek R; Szeto L; Vokes EE
J Clin Oncol; 2004 Mar; 22(6):1110-7. PubMed ID: 15020613
[TBL] [Abstract][Full Text] [Related]
6. A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer.
Tolcher AW; Chi K; Kuhn J; Gleave M; Patnaik A; Takimoto C; Schwartz G; Thompson I; Berg K; D'Aloisio S; Murray N; Frankel SR; Izbicka E; Rowinsky E
Clin Cancer Res; 2005 May; 11(10):3854-61. PubMed ID: 15897586
[TBL] [Abstract][Full Text] [Related]
7. Randomized Phase II study comparing paclitaxel and carboplatin versus mitoxantrone in patients with hormone-refractory prostate cancer.
Cabrespine A; Guy L; Khenifar E; Curé H; Fleury J; Penault-Llorca F; Kwiatkowski F; Barthomeuf C; Chollet P; Bay JO
Urology; 2006 Feb; 67(2):354-9. PubMed ID: 16442593
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of mitoxantrone and ketoconazole for hormone-refractory prostate cancer.
Eklund J; Kozloff M; Vlamakis J; Starr A; Mariott M; Gallot L; Jovanovic B; Schilder L; Robin E; Pins M; Bergan RC
Cancer; 2006 Jun; 106(11):2459-65. PubMed ID: 16615097
[TBL] [Abstract][Full Text] [Related]
9. A phase I trial of weekly paclitaxel, 13- cis-retinoic acid, and interferon alpha in patients with prostate cancer and other advanced malignancies.
Thalasila A; Poplin E; Shih J; Dvorzhinski D; Capanna T; Doyle-Lindrud S; Beers S; Goodin S; Rubin E; DiPaola RS
Cancer Chemother Pharmacol; 2003 Aug; 52(2):119-24. PubMed ID: 12768320
[TBL] [Abstract][Full Text] [Related]
10. Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate.
Mackler NJ; Dunn RL; Hellerstedt B; Cooney KA; Fardig J; Olson K; Pienta KJ; Smith DC
Cancer; 2006 Jun; 106(12):2617-23. PubMed ID: 16691618
[TBL] [Abstract][Full Text] [Related]
11. Phase I clinical and pharmacokinetic study of kahalalide F in patients with advanced androgen refractory prostate cancer.
Rademaker-Lakhai JM; Horenblas S; Meinhardt W; Stokvis E; de Reijke TM; Jimeno JM; Lopez-Lazaro L; Lopez Martin JA; Beijnen JH; Schellens JH
Clin Cancer Res; 2005 Mar; 11(5):1854-62. PubMed ID: 15756010
[TBL] [Abstract][Full Text] [Related]
12. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer.
Chan JS; Beer TM; Quinn DI; Pinski JK; Garzotto M; Sokoloff M; Dehaze DR; Ryan CW
BJU Int; 2008 Dec; 102(11):1601-6. PubMed ID: 18782306
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity.
Marcucci G; Stock W; Dai G; Klisovic RB; Liu S; Klisovic MI; Blum W; Kefauver C; Sher DA; Green M; Moran M; Maharry K; Novick S; Bloomfield CD; Zwiebel JA; Larson RA; Grever MR; Chan KK; Byrd JC
J Clin Oncol; 2005 May; 23(15):3404-11. PubMed ID: 15824414
[TBL] [Abstract][Full Text] [Related]
15. A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer.
Tolcher AW; Reyno L; Venner PM; Ernst SD; Moore M; Geary RS; Chi K; Hall S; Walsh W; Dorr A; Eisenhauer E
Clin Cancer Res; 2002 Aug; 8(8):2530-5. PubMed ID: 12171880
[TBL] [Abstract][Full Text] [Related]
16. A modified low-dose regimen of mitoxantrone and prednisolone in patients with androgen-independent prostate cancer.
Sheen WC; Chen JS; Wang HM; Yang TS; Liaw CC; Lin YC
Jpn J Clin Oncol; 2004 Jun; 34(6):337-41. PubMed ID: 15333686
[TBL] [Abstract][Full Text] [Related]
17. A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer.
Cunningham CC; Holmlund JT; Schiller JH; Geary RS; Kwoh TJ; Dorr A; Nemunaitis J
Clin Cancer Res; 2000 May; 6(5):1626-31. PubMed ID: 10815879
[TBL] [Abstract][Full Text] [Related]
18. [Therapy of hormone refractory prostate carcinoma with mitoxantrone. A clinical phase II study].
Otto T; Rembrink K; Goepel M; Krege S; Meyer-Schwiekerath M; Rübben H
Urologe A; 1996 Mar; 35(2):142-5. PubMed ID: 8650848
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of tesmilifene plus mitoxantrone and prednisone for hormone refractory prostate cancer: high subjective and objective response in patients with symptomatic metastases.
Raghavan D; Brandes LJ; Klapp K; Snyder T; Styles E; Tsao-Wei D; Lieskovsky G; Quinn DI; Ramsey EW
J Urol; 2005 Nov; 174(5):1808-13; discussion 1813. PubMed ID: 16217292
[TBL] [Abstract][Full Text] [Related]
20. Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy.
Yoshino T; Shiina H; Urakami S; Kikuno N; Yoneda T; Shigeno K; Igawa M
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6116-24. PubMed ID: 17062688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
